Black Rock Inc. Codiak Bio Sciences, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.32 - $0.9 $40,028 - $112,580	-125,089 Reduced 39.97%	187,833 $75,000
Q3 2022 Nov 14, 2022	SELL	$0.82 - $3.19 $10,054 - $39,112	-12,261 Reduced 3.77%	312,922 $245,000
Q2 2022 Aug 12, 2022	SELL	$2.24 - $6.96 $1.59 Million - $4.93 Million	-709,012 Reduced 68.56%	325,183 $936,000
Q1 2022 May 12, 2022	SELL	$4.3 - $12.95 $62,848 - $189,277	-14,616 Reduced 1.39%	1,034,195 $6.49 Million
Q4 2021 Feb 10, 2022	BUY	$10.0 - $16.78 $1.23 Million - $2.06 Million	122,632 Added 13.24%	1,048,811 $11.7 Million
Q3 2021 Nov 09, 2021	BUY	$15.58 - $22.88 $654,562 - $961,257	42,013 Added 4.75%	926,179 $15.1 Million
Q2 2021 Aug 11, 2021	BUY	$11.72 - $26.81 $10.4 Million - $23.7 Million	884,166 New	884,166 $16.4 Million

238K

Ticker CDAK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,995,200
Market Cap $360K
Description
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.